Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

Last updated:
2026-07-25
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA

Intervention/treatment:
FEVIPIPRANT (QAW039)
Medical condition:
ASTHMA
Protocol code:
CQAW039A2314
Control number:
188286
Status:
Closed
Approved:
November 03, 2015
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02563067
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
12 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Study Director
Organization
Novartis Pharmaceuticals
Phone:
862-778-8300
Sponsor
NOVARTIS PHARMACEUTICALS CANADA INC

Locations

British Columbia

Novartis Investigative Site
Vancouver, British Columbia, V5Z 1M9
Novartis Investigative Site
Vancouver BC, British Columbia, V6Z 1Y6

Quebec

Novartis Investigative Site
Montreal, Quebec, H3G 1L5
Novartis Investigative Site
Montreal, Quebec, H4J 1C5
Novartis Investigative Site
Québec, Quebec, G1V 4W2

Results

See the results from the trial NCT02563067. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?